1. Home
  2. IMNM vs BCRX Comparison

IMNM vs BCRX Comparison

Compare IMNM & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.03

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo BioCryst Pharmaceuticals Inc.

BCRX

BioCryst Pharmaceuticals Inc.

HOLD

Current Price

$8.49

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
BCRX
Founded
2006
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
IMNM
BCRX
Price
$22.03
$8.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
11
Target Price
$32.80
$20.82
AVG Volume (30 Days)
915.1K
4.5M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
381.40
EPS
N/A
N/A
Revenue
$6,941,000.00
$25,186,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,127.34
$12.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.96
$6.00
52 Week High
$27.65
$11.31

Technical Indicators

Market Signals
Indicator
IMNM
BCRX
Relative Strength Index (RSI) 48.94 42.58
Support Level $19.23 $7.94
Resistance Level $23.24 $8.68
Average True Range (ATR) 1.27 0.46
MACD -0.05 -0.07
Stochastic Oscillator 55.07 34.89

Price Performance

Historical Comparison
IMNM
BCRX

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Share on Social Networks: